BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20516572)

  • 1. Coevolution and HBV drug resistance.
    Khudyakov Y
    Antivir Ther; 2010; 15(3 Pt B):505-15. PubMed ID: 20516572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HBV mutations during antiviral therapy in patients with chronic hepatitis B].
    Hwang SG
    Korean J Hepatol; 2005 Dec; 11(4):311-9. PubMed ID: 16380660
    [No Abstract]   [Full Text] [Related]  

  • 3. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hepatitis B patients with antiviral resistance.
    Fung SK; Lok AS
    Antivir Ther; 2004 Dec; 9(6):1013-26. PubMed ID: 15651760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.
    Teo CG; Locarnini SA
    Antivir Ther; 2010; 15(3 Pt B):445-9. PubMed ID: 20516564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Definitions of resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Zoulim F
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S9-11. PubMed ID: 17075488
    [No Abstract]   [Full Text] [Related]  

  • 8. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus genetic diversity.
    Echevarría JM; Avellón A
    J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic hepatitis B and the implications of viral resistance to therapy.
    Mauss S; Wedemeyer H
    Expert Rev Anti Infect Ther; 2008 Apr; 6(2):191-9. PubMed ID: 18380601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of antiviral resistance in patients with chronic hepatitis B.
    Locarnini S; Hatzakis A; Heathcote J; Keeffe EB; Liang TJ; Mutimer D; Pawlotsky JM; Zoulim F
    Antivir Ther; 2004 Oct; 9(5):679-93. PubMed ID: 15535405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus].
    Song JW; Lin JS; Kong XJ; Liang KH
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):361-3. PubMed ID: 12837218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of PCR-LDR-nucleic acid detection strip in detection of YMDD mutation in hepatitis B patients treated with lamivudine.
    Xu G; You Q; Pickerill S; Zhong H; Wang H; Shi J; Luo Y; You P; Kong H; Lu F; Hu L
    J Med Virol; 2010 Jul; 82(7):1143-9. PubMed ID: 20513076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis and recombinant construction of HBV the reverse transcriptase gene with drug-resistant mutations from 40 patients with chronic hepatitis B].
    Su HL; Liu Y; Liu W; Zhong YW; Chen XY; Wang CM; Liu YM; Xu DP
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):340-2. PubMed ID: 20387480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genesis of drug-resistant and vaccine-escape HBV mutants.
    Locarnini SA; Yuen L
    Antivir Ther; 2010; 15(3 Pt B):451-61. PubMed ID: 20516565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to overcome antiviral-resistant hepatitis B virus?
    Song BC
    Intervirology; 2010; 53(1):29-38. PubMed ID: 20068338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
    Fournier C; Zoulim F
    Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
    Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.